ХАРАКТЕРИСТИКА БОЛЕЗНИ ПАРКИНСОНА: ПРОГРЕССИРОВАНИЕ ОСНОВНЫХ СИМПТОМОВ
Ключевые слова:
Болезнь Паркинсона; нейродегенерация; тело Леви; окислительный стресс; клинические критерии.Аннотация
Болезнь Паркинсона (БП) - сложное нейродегенеративное заболевание, характеризующееся сочетанием двигательных и недвигательных симптомов, не имеющих четко определенных диагностических клинических маркеров. Первичные двигательные признаки, такие как брадикинезия, тремор покоя, ригидность и потеря постуральных рефлексов, являются основными признаками, используемыми в современной клинической практике для идентификации пациентов с БП.
Библиографические ссылки
Parkinson, J. An essay on the Shaking Palsy. Arch. Neurol. 1969, 20, 441–445.
Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896–912.
Mhyre, T.R.; Boyd, J.T.; Hamill, R.W.; Maguire-Zeiss, K.A. Parkinson’s disease. Subcell Biochem. 2012, 65, 389–455.
Hirsch, L.; Jette, N.; Frolkis, A.; Steeves, T.; Pringsheim, T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2016, 46, 292–300.
Driver, J.A.; Logroscino, G.; Gaziano, J.M.; Kurth, T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009, 72, 432–438.
Lee, Y.H.; Cha, J.; Chung, S.J.; Yoo, H.S.; Sohn, Y.H.; Ye, B.S.; Lee, P.H. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease. Sci. Rep. 2019, 9, 10531.
Wirdefeldt, K.; Gatz, M.; Pawitan, Y.; Pedersen, N.L. Risk and protective factors for Parkinson’s disease: A study in Swedish twins. Ann. Neurol. 2005, 57, 27–33
Prediger, R.D. Effects of caffeine in Parkinson’s disease: From neuroprotection to the management of motor and non-motor symptoms. J. Alzheimer’s Dis. JAD 2010, 20, S205–S220.
Huse, D.M.; Schulman, K.; Orsini, L.; Castelli-Haley, J.; Kennedy, S.; Lenhart, G. Burden of illness in Parkinson’s disease. Mov. Disord.: Off. J. Mov. Disord. Soc. 2005, 20, 1449–1454.
Findley, L.J. The economic impact of Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, S8–S12
Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 368–376
Rizek, P.; Kumar, N.; Jog, M.S. An update on the diagnosis and treatment of Parkinson disease. CMAJ: Can. Med. Assoc. J. J. l’Assoc. Med. Can. 2016, 188, 1157–1165.
D’Costa, D.F.; Sheehan, L.J.; Phillips, P.A.; Moore-Smith, B. The levodopa test in Parkinson’s disease. Age Ageing 1995, 24, 210–212.
Massano, J.; Bhatia, K.P. Clinical approach to Parkinson’s disease: Features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2012, 2, a008870.
Meara, J.; Bhowmick, B.K.; Hobson, P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 1999, 28, 99–102
Nandipati, S.; Litvan, I. Environmental Exposures and Parkinson’s Disease. Int. J. Environ. Res. Public Health 2016, 13, 881.
Lock, E.A.; Zhang, J.; Checkoway, H. Solvents and Parkinson disease: A systematic review of toxicological and epidemiological evidence. Toxicol. Appl. Pharmacol. 2013, 266, 345–355.
Lai, C.-Y.; Chou, M.-C.; Lin, C.-L.; Kao, C.-H. Increased risk of Parkinson disease in patients with carbon monoxide intoxication: A population-based cohort study. Medicine 2015, 94, e869.
Kenborg, L.; Rugbjerg, K.; Lee, P.-C.; Ravnskjær, L.; Christensen, J.; Ritz, B.; Lassen, C.F. Head injury and risk for Parkinson disease: Results from a Danish case-control study. Neurology 2015, 84, 1098–1103
Selvaraj, S.; Piramanayagam, S. Impact of gene mutation in the development of Parkinson’s disease. Genes Dis. 2019, 6, 120–128.
Hauser, D.N.; Hastings, T.G. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol. Dis. 2013, 51, 35–42.
McCann, H.; Stevens, C.H.; Cartwright, H.; Halliday, G.M. alpha-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 2014, 20, S62–S67.
Burré, J. The Synaptic Function of α-Synuclein. J. Parkinson’s Dis. 2015, 5, 699–713.
Guardia-Laguarta, C.; Area-Gomez, E.; Schon, E.A.; Przedborski, S. Novel subcellular localization for α-synuclein: Possible functional consequences. Front. Neuroanat. 2015, 9, 17.
Siddiqui, I.J.; Pervaiz, N.; Abbasi, A.A. The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Sci. Rep. 2016, 6, 24475.
Wakabayashi, K.; Tanji, K.; Mori, F.; Takahashi, H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 2007, 27, 494–506
Gibson, G.E.; Park, L.C.; Sheu, K.F.; Blass, J.P.; Calingasan, N.Y. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 2000, 36, 97–112.
Schapira, A.H.V.; Cooper, J.M.; Dexter, D.; Clark, J.B.; Jenner, P.; Marsden, C.D. Mitochondrial Complex I Deficiency in Parkinson’s Disease. J. Neurochem. 1990, 54, 823–827.
McNaught, K.; Olanow, C. Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease. Ann. Neurol. 2003, 53, S73–S84.
Ebrahimi-Fakhari, D.; Wahlster, L.; McLean, P.J. Molecular chaperones in Parkinson’s disease--present and future. J. Parkinson’s Dis. 2011, 1, 299–320.
Murphy, K.E.; Gysbers, A.M.; Abbott, S.K.; Spiro, A.S.; Furuta, A.; Cooper, A.; Garner, B.; Kabuta, T.; Halliday, G.M. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov. Disord. 2015, 30, 1639–1647.
Riboldi, G.M.; Di Fonzo, A.B. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019, 8, 364.
Berardelli, A.; Rothwell, J.C.; Thompson, P.D.; Hallett, M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 2001, 124, 2131–2146.
Vingerhoets, F.J.; Schulzer, M.; Calne, D.B.; Snow, B.J. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann. Neurol. 1997, 41, 58–64.
Jankovic, J.; Schwartz, K.S.; Ondo, W. Re-emergent tremor of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1999, 67, 646–650
Shahed, J.; Jankovic, J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, 67–76
Riley, D.; Lang, A.E.; Blair, R.D.; Birnbaum, A.; Reid, B. Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1989, 52, 63–66.
Williams, D.R.; Watt, H.C.; Lees, A.J. Predictors of falls and fractures in bradykinetic rigid syndromes: A retrospective study. J. Neurol. Neurosurg. Psychiatry 2006, 77, 468–473.
Shivitz, N.; Koop, M.M.; Fahimi, J.; Heit, G.; Bronte-Stewart, H.M. Bilateral subthalamic nucleus deep brain stimulation improves certain aspects of postural control in Parkinson’s disease, whereas medication does not. Mov. Disord. Off. J. Mov. Disord. 2006, 21, 1088–1097.
Carlsson, A.; Lindqvist, M.; Magnusson, T.O.R. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 1957, 180, 1200.
Goldenberg, M.M. Medical management of Parkinson’s disease. Pharm. Ther. 2008, 33, 590–606.
Papavasiliou, P.S.; Cotzias, G.C.; Duby, S.E.; Steck, A.J.; Fehling, C.; Bell, M.A. Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 1972, 286, 8–14.
Fox, S.H.; Lang, A.E. Levodopa-related motor complications—Phenomenology. Mov. Disord. 2008, 23, S509–S514
Schapira, A.; Olanow, C.W. Principles Of Treatment In Parkinson’s Disease; Elsevier Health Sciences: Amsterdam, The Netherlands, 2005.
Jankovic, J.; Aguilar, L.G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2008, 4, 743–757.
Опубликован
Выпуск
Раздел
Лицензия
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Как цитировать
